Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Verastem, Inc. - Common Stock
(NQ:
VSTM
)
4.890
-0.770 (-13.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verastem, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Verastem Q1 Earnings Call Highlights
↗
May 09, 2026
Verastem (NASDAQ:VSTM) reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent low-grade...
Via
MarketBeat
Topics
Earnings
Verastem (VSTM) Q1 2026 Earnings Transcript
↗
May 08, 2026
Verastem (VSTM) Q1 2026 Earnings Transcript
Via
The Motley Fool
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
May 08, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Inc (NASDAQ:VSTM) Mixed Q1 Results Disappoint on Revenue Miss
↗
May 07, 2026
Via
Chartmill
Verastem Inc. (NASDAQ:VSTM) Reports Strong Q4 Revenue Beat, Narrows Loss Amid Product Launch
↗
March 04, 2026
Via
Chartmill
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
May 07, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
April 30, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
April 23, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
April 10, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
March 17, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers
March 17, 2026
From
Verastem Oncology
Via
Business Wire
Verastem (VSTM) Q4 2025 Earnings Call Transcript
↗
March 05, 2026
Verastem (VSTM) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss?
↗
March 04, 2026
The company flagged several catalysts ahead, including early VS-7375 data in the first half of the year, and Ramp 205 pancreatic cancer study results in Q2.
Via
Stocktwits
Topics
Earnings
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
March 04, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
February 18, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
February 04, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2026
From
Verastem Oncology
Via
Business Wire
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits
↗
December 29, 2025
A full exit during a volatile stretch raises a sharper question than timing alone.
Via
The Motley Fool
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer
↗
December 29, 2025
The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data.
Via
Stocktwits
Topics
Supply Chain
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
December 29, 2025
From
Verastem Oncology
Via
Business Wire
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table
↗
December 28, 2025
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.
Via
The Motley Fool
Topics
Regulatory Compliance
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away
↗
December 28, 2025
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.
Via
The Motley Fool
Topics
Regulatory Compliance
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
December 15, 2025
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
November 25, 2025
From
Verastem Oncology
Via
Business Wire
Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
November 14, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
November 14, 2025
Via
Benzinga
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
November 14, 2025
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Proposed Public Offering of Common Stock
November 13, 2025
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Present at Upcoming Investor Conferences
November 05, 2025
From
Verastem Oncology
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
